Back to top
January 18, 2018
FDA Review: Clobazam Oral Soluble Film for Treating Lennox-Gastaut Syndrome
Research, Treatments

The U.S. Food and Drug Administration has accepted for review a New Drug Application for clobazam Oral Soluble Film (clobazam OSF) for adjunctive treatment of seizures associated with Lennox-Gastaut syndrome in patients two years of age or older. The target date for completion of the FDA review is the third-quarter of 2018.
 
Clobazam OSF is administered using Aquestive's PharmFilm drug delivery technology. Similar in size and thickness to a stamp, Aquestive's PharmFilm dissolves instantly after being placed on the tongue and can be administered without water.

Two multicenter controlled studies were conducted to evaluate the bioequivalence of clobazam OSF with clobazam tablets, a benzodiazepine currently on market, at the same dosage strengths. Based on the studies, clobazam OSF was demonstrated to be bioequivalent to clobazam tablets and have comparable safety.

Learn More

 

Related News

October 2, 2018
Whole-Brain Connectome Maps Teach Artificial Intelligence...

Medical University of South Carolina (MUSC) neurologists have developed a new method based on artificial intelligence that may eventually help...

Read More
October 1, 2018
Diagnostic Efficacy And Study Quality Of Home Video...

The diagnostic efficacy and study quality of home video telemetry and inpatient video telemetry are similar in paediatric patients. Home video...

Read More
October 1, 2018
High Electroencephalographic Seizure Exposure Is Associated...

Among neonates with hypoxic-ischemic encephalopathy managed with therapeutic hypothermia, high electroencephalographic seizure exposure was the...

Read More